Innate Pharma (OTCMKTS:IPHYF) Stock Price Up 57.2% - Here's Why

Key Points

• Innate Pharma's stock price surged 57.2% on Monday, closing at $2.06, significantly higher than its previous close of $1.31.
• The company is a biotechnology firm focused on developing immunotherapies for cancer, with several products in various phases of clinical trials.
• Current trials include Lacutamab for skin lymphomas and Monalizumab for advanced solid tumors, indicating ongoing research and potential breakthroughs.

Innate Pharma SA (OTCMKTS:IPHYF - Get Free Report) shares were up 57.2% on Monday . The stock traded as high as $2.06 and last traded at $2.06. Approximately 300 shares traded hands during mid-day trading, The stock had previously closed at $1.31.

Innate Pharma Price Performance

The company's fifty day simple moving average is $1.56 and its two-hundred day simple moving average is $1.99.

About Innate Pharma

Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.